A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Recruiting now · Phase 1
Conditions studied: Systemic Lupus Erythematosus, Rheumatoid Arthritis
In brief
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety of ABBV-519 in adult participants with SLE or RA. This is a single ascending dose study in an estimated 30 adult participants with moderate SLE or RA. The total duration of the study will be approximately 425 days (60-day Screening Period, 1-day Treatment Period, and a 52 week Follow-up Period) at approximately 15 to 20 sites globally. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Key facts
- Study ID
- NCT07607964
- Run by
- AbbVie
- People needed
- 30
- Starts
- 2026-05-28
- Expected to finish
- 2029-01-01
- Last updated by the study team
- 2026-07-01
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Key Inclusion Criteria:
- Individuals between 18 and 75 years of age inclusive at the time of Screening.
- Minimum baseline B-cell count of 50 cells/mcL.
- Inclusion Criteria for SLE Participants:
- Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria.
- Positive ANA ≥ 1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double-stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or anti-Sjogren's syndrome antigen A (SSA).
- Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score of ≥ 4 (excluding anti-dsDNA and C3/C4). Lupus headache or organic brain syndrome do not count towards the hSLEDAI points required for eligibility.
- Participants must have an inadequate response to ≥ 1 immunosuppressant therapies, used for at least 3 months.
- Inclusion Criteria for RA Participants:
- Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA.
- Presence of rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA) above the ULN.
- Presence of at least 6 swollen and 6 tender joints
- High-sensitivity C-reactive protein (hs-CRP) ≥ 3 mg/L.
- Failed at least 1 conventional synthetic disease-modifying antirheumatic drug (DMARD) and ≥ 1 biological or targeted DMARDs of different classes.
You may not qualify if…
- Key Exclusion Criteria:
- Participants with a history of infection.
- Participants with uncontrolled hypertension
- Exclusion for SLE Participants:
- Active neuropsychiatric SLE, or signs or symptoms of neuropsychiatric SLE within the 6 months prior to Screening (lupus headache permissible).
- Unstable or progressive glomerulonephritis (active class III or IV).
- SLE overlap syndromes including, but not limited to RA, Sjogren's disease (SjD), SSc, polymyositis, dermatomyositis, or mixed connective tissue disease.
- Exclusion for RA Participants:
- - History of RA overlap syndromes, including but not limited to SLE, SjD, scleroderma, mixed connective tissue disorder or polymyositis.
Where it is running
- Epic Medical Research /ID# 279180 — Red Oak, Texas, United States (enrolling)
- Pinnacle Research Group /ID# 278677 — Anniston, Alabama, United States (enrolling)
- Solace Research /ID# 279155 — Tustin, California, United States (enrolling)
- Clinical Research Of West Florida - Phase I Unit /ID# 279292 — Clearwater, Florida, United States (enrolling)
- Finlay Medical Research - Greenacres /ID# 278380 — Greenacres City, Florida, United States (enrolling)
- Clinical Research of Osceola /ID# 278374 — Kissimmee, Florida, United States (enrolling)
- Discovery Health Research Center /ID# 279691 — Plantation, Florida, United States (enrolling)
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 279130 — Tampa, Florida, United States (enrolling)
- Advanced Quality Medical Research /ID# 279147 — Orland Park, Illinois, United States (enrolling)
- UCLA Health West Medical Campus /ID# 282811 — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.